MIP Discovery, an innovative developer of non-biological affinity reagents designed to accelerate the development and production of cell and gene therapies, has closed a £7 million Series A financing round led by Mercia Ventures.  Existing investor Calculus Capital also participated in the round, along with angel investors. The investment marks a pivotal change for MIP … Continue reading MIP Discovery raises £7m to advance cell and gene therapies